Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

Andrew Joseph covers well being, medication, and the biopharma business in Europe. You may attain Andrew on Sign at drewqjoseph.71.

LONDON — The French pharma firm Servier stated Friday that it could purchase Day One Biopharmaceuticals, the maker of a drug for childhood mind tumors, in a deal price roughly $2.5 billion. 

Servier, which is privately held, is paying $21.50 a share in money for Day One, a roughly 68% premium on the Bay Space biotech’s closing worth on Thursday. 

The deal’s centerpiece is Day One’s Ojemda, which received U.S. approval in 2024 as a remedy for pediatric low-grade glioma, the most typical type of childhood mind most cancers. Servier additionally stated the deal would broaden its pipeline of experimental medicines for uncommon cancers.